Revance Therapeutics (NASDAQ:RVNC) had its price target increased by SunTrust Banks to $53.00 in a research note issued to investors on Friday, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock.
Several other brokerages also recently issued reports on RVNC. Zacks Investment Research upgraded Revance Therapeutics from a hold rating to a buy rating and set a $26.00 price objective for the company in a research report on Wednesday, August 30th. ValuEngine downgraded Revance Therapeutics from a hold rating to a sell rating in a research report on Monday, December 4th. BidaskClub upgraded Revance Therapeutics from a sell rating to a hold rating in a research report on Friday, August 18th. Cantor Fitzgerald reiterated a buy rating and set a $50.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, September 26th. Finally, Piper Jaffray Companies boosted their price objective on Revance Therapeutics from $28.00 to $51.00 and gave the stock an overweight rating in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $42.11.
Revance Therapeutics (RVNC) opened at $35.95 on Friday. Revance Therapeutics has a 52 week low of $15.90 and a 52 week high of $37.20.
Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business’s revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.64) earnings per share. equities research analysts expect that Revance Therapeutics will post -3.73 EPS for the current fiscal year.
In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $24.94, for a total value of $189,544.00. Following the transaction, the chief executive officer now owns 133,188 shares of the company’s stock, valued at $3,321,708.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mark J. Foley purchased 20,000 shares of the company’s stock in a transaction on Tuesday, November 7th. The stock was bought at an average cost of $26.96 per share, for a total transaction of $539,200.00. Following the acquisition, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $161,760. The disclosure for this purchase can be found here. Insiders sold 44,026 shares of company stock valued at $1,135,234 over the last 90 days. 18.86% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of RVNC. Franklin Resources Inc. increased its holdings in shares of Revance Therapeutics by 13.1% in the second quarter. Franklin Resources Inc. now owns 3,375,238 shares of the biopharmaceutical company’s stock valued at $89,106,000 after buying an additional 391,638 shares in the last quarter. Jennison Associates LLC acquired a new stake in Revance Therapeutics during the 2nd quarter valued at $9,990,000. Bank of New York Mellon Corp raised its stake in Revance Therapeutics by 14.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,079,562 shares of the biopharmaceutical company’s stock valued at $54,901,000 after purchasing an additional 261,764 shares during the period. JPMorgan Chase & Co. raised its stake in Revance Therapeutics by 4.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,626,603 shares of the biopharmaceutical company’s stock valued at $95,743,000 after purchasing an additional 166,759 shares during the period. Finally, PointState Capital LP raised its stake in Revance Therapeutics by 58.5% during the 2nd quarter. PointState Capital LP now owns 438,200 shares of the biopharmaceutical company’s stock valued at $11,568,000 after purchasing an additional 161,700 shares during the period. 88.58% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://ledgergazette.com/2017/12/12/suntrust-banks-boosts-revance-therapeutics-rvnc-price-target-to-53-00.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.